Full Text View
Tabular View
No Study Results Posted
Related Studies
Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.
This study is currently recruiting participants.
Verified by University Hospital, Strasbourg, France, November 2009
First Received: June 21, 2006   Last Updated: November 20, 2009   History of Changes
Sponsor: University Hospital, Strasbourg, France
Information provided by: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00343213
  Purpose

P16INK4a has recently been described as a surrogate marker for HR-HPV associated squamous and glandular intraepithelial lesions of the cervix. The immunohistochemical staining pattern of p16INK4a in high grade intraepithelial neoplasia of the cervix (CIN 2 and 3) is diffuse, whereas in CIN 1 different staining patterns (diffuse, sporadic, focal or negative) can be seen. The aim of our study is to find out whether the p16INK4a staining pattern of CIN 1 is able to predict the outcome of the lesion. The retrospective part of the study includes cervical biopsies of 200 patients with CIN 1 and clinical follow-up for at least 5 years. p16INK4a staining and HPV detection by IHC will be correlated to clinical outcome.The prospective part of the study includes 300 patients with CIN 1 and LSIL on cytology. HPV detection by HCII and p16INK4a immunohistochemistry on liquid based cytology samples as well as p16INK4a staining and HPV detection by ISH on colposcopy guided biopsies will be correlated to clinical follow-up and colposcopy findings. Slides are analysed by 2 pathologists without knowledge of clinical data.


Condition Intervention
Cervical Intraepithelial Neoplasia Grade 1 (CIN 1)
Procedure: colposcopy

Study Type: Interventional
Study Design: Prevention, Non-Randomized, Double-Blind, Historical Control, Factorial Assignment, Efficacy Study
Official Title: Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Immunohistochemical Study on Biopsies (Retrospective and Prospective Analysis) and on Liquid Based (SurePath) Cervical Cytology (Prospective Analysis). Correlation With HPV Typing and Clinical Outcome.

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • p16INK4a staining pattern and HPV status of the initial biopsy

Secondary Outcome Measures:
  • p16INK4a staining pattern and histologic diagnosis of follow-up biopsies correlated with colposcopic findings.

Estimated Enrollment: 300
Study Start Date: June 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Responsible women > 18 years with histologically proven CIN 1

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00343213

Contacts
Contact: Jean-Jacques Baldauf, MD 3.33.88.12.74.59 jean-jacques.baldauf@chru-strasbourg.fr
Contact: Gerlinde Averous 3.33.88.12.70.52 gerlinde.averous@chru-strasbourg.fr

Locations
France
Département de Gynécologie-Obstétrique - Hôpital de Hautepierre Recruiting
Strasbourg, France, 67098
Contact: Jean-Jacques Baldauf, MD     3.33.88.12.74.59     jean-jacques.baldauf@chru-strasbourg.fr    
Service de gynécologie-obtétrique - Centre Hospitalier Général Recruiting
Saverne, France
Contact: Jean-Luc Harter, MD     3.33.88.71.65.17     jeanluc.harter@ch-saverne.fr    
Service de Gynécologie-Obstétrique - Centre Hospitalier Général Recruiting
Haguenau, France
Contact: Dominique Collin, MD     3.33.88.06.30.67     dominique.collin@ch-haguenau.fr    
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Jean-Jacques Baldauf, MD Département de Gynécologie-Obstétrique - Hôpital de Hautepierre - Strasbourg - France
  More Information

No publications provided

Responsible Party: Hôpitaux Universitaires de Strasbourg ( Christine GEILLER, Directeur de la Recherche Clinique et des Innovations )
Study ID Numbers: 3454
Study First Received: June 21, 2006
Last Updated: November 20, 2009
ClinicalTrials.gov Identifier: NCT00343213     History of Changes
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:
Prognostic value of p16INK4a
CIN 1
LSIL
HPV

Additional relevant MeSH terms:
Genital Diseases, Female
Uterine Cervical Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Carcinoma in Situ
Uterine Diseases
Uterine Cervical Dysplasia
Neoplasms, Glandular and Epithelial
Carcinoma
Cervical Intraepithelial Neoplasia

ClinicalTrials.gov processed this record on February 08, 2010